HWM
CASI icon

HighMark Wealth Management’s CASI Pharmaceuticals CASI Stock Holding History

HighMark Wealth Management’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1
Closed – – 453
2020
Q3 		$0 Hold
1
– – ﹤0.01% 449
2020
Q2 		$0 Hold
1
– – ﹤0.01% 435
2020
Q1 		$0 Hold
1
– – ﹤0.01% 358
2019
Q4 		$0 Buy
+1
New +$32 ﹤0.01% 391

Other funds holding CASI

IACGFIA
IDG-Accel China Growth Fund III Associates Hong Kong $31.2M AUM 2.97% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighMark Wealth Management's CASI Position: Q4 2020 in Review

HighMark Wealth Management sold out of CASI Pharmaceuticals (CASI) in Q4 2020, closing a stake of 1 share.

HighMark Wealth Management first reported a position in CASI in Q4 2019 and held it in 4 quarters. The position peaked at $0 in Q3 2020. 73 funds tracked by Wall St. Rank hold CASI as of Q4 2020.

  • HighMark Wealth Management reported no remaining CASI Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • HighMark Wealth Management sold 1 CASI Pharmaceuticals share in Q4 2020.
  • HighMark Wealth Management first reported a position in CASI Pharmaceuticals in Q4 2019 and held it in 4 quarters.
  • HighMark Wealth Management's CASI Pharmaceuticals position peaked at $0 in Q3 2020.
  • 73 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q4 2020.

Based on HighMark Wealth Management's 13F filing for Q4 2020, filed 27 Jan 2021.